Siddhartha Mitra
Concepts (362)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 21 | 2025 | 1282 | 2.790 |
Why?
| | Glioma | 8 | 2025 | 418 | 2.300 |
Why?
| | Glioblastoma | 11 | 2023 | 344 | 1.970 |
Why?
| | Phagocytosis | 8 | 2025 | 291 | 1.510 |
Why?
| | Medulloblastoma | 7 | 2023 | 218 | 1.270 |
Why?
| | CD47 Antigen | 8 | 2025 | 43 | 1.140 |
Why?
| | Cerebellar Neoplasms | 4 | 2023 | 179 | 1.060 |
Why?
| | Macrophages | 9 | 2025 | 1478 | 1.020 |
Why?
| | Macrophage Activation | 1 | 2025 | 192 | 0.850 |
Why?
| | Tumor Microenvironment | 4 | 2024 | 711 | 0.680 |
Why?
| | Neurons | 9 | 2017 | 1611 | 0.670 |
Why?
| | Microglia | 2 | 2020 | 254 | 0.650 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2021 | 72 | 0.640 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 840 | 0.580 |
Why?
| | Neoplastic Stem Cells | 6 | 2022 | 411 | 0.560 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2020 | 75 | 0.530 |
Why?
| | Cell Line, Tumor | 19 | 2025 | 3502 | 0.520 |
Why?
| | Rhabdoid Tumor | 3 | 2025 | 100 | 0.520 |
Why?
| | Neural Stem Cells | 2 | 2015 | 160 | 0.500 |
Why?
| | Nerve Tissue Proteins | 7 | 2015 | 605 | 0.490 |
Why?
| | Nuclear Proteins | 6 | 2018 | 718 | 0.470 |
Why?
| | Meningomyelocele | 1 | 2015 | 61 | 0.450 |
Why?
| | Immunotherapy | 6 | 2021 | 641 | 0.440 |
Why?
| | Craniopharyngioma | 2 | 2025 | 78 | 0.410 |
Why?
| | Oligodendroglia | 1 | 2015 | 178 | 0.410 |
Why?
| | Huntington Disease | 3 | 2010 | 64 | 0.410 |
Why?
| | Animals | 42 | 2025 | 37328 | 0.400 |
Why?
| | Inclusion Bodies | 4 | 2011 | 27 | 0.390 |
Why?
| | Teratoma | 3 | 2025 | 121 | 0.390 |
Why?
| | Oncogene Protein pp60(v-src) | 1 | 2012 | 4 | 0.390 |
Why?
| | Pituitary Neoplasms | 2 | 2025 | 194 | 0.390 |
Why?
| | Signal Transduction | 9 | 2019 | 5116 | 0.380 |
Why?
| | Connexin 43 | 1 | 2012 | 35 | 0.370 |
Why?
| | Mice | 26 | 2025 | 17969 | 0.370 |
Why?
| | Ion Channel Gating | 1 | 2012 | 91 | 0.370 |
Why?
| | Gap Junctions | 1 | 2012 | 63 | 0.360 |
Why?
| | ErbB Receptors | 6 | 2013 | 612 | 0.360 |
Why?
| | Oocytes | 1 | 2012 | 176 | 0.350 |
Why?
| | Receptors, Immunologic | 3 | 2019 | 207 | 0.340 |
Why?
| | Antineoplastic Agents | 6 | 2025 | 2162 | 0.320 |
Why?
| | Ependymoma | 2 | 2023 | 165 | 0.310 |
Why?
| | Immunization, Passive | 1 | 2010 | 88 | 0.310 |
Why?
| | B7 Antigens | 2 | 2020 | 14 | 0.310 |
Why?
| | Antibodies, Monoclonal | 5 | 2025 | 1456 | 0.310 |
Why?
| | Cell Proliferation | 10 | 2022 | 2502 | 0.300 |
Why?
| | Imidazoles | 3 | 2020 | 251 | 0.300 |
Why?
| | Ubiquitin | 1 | 2008 | 72 | 0.290 |
Why?
| | Humans | 55 | 2025 | 141284 | 0.290 |
Why?
| | Xenograft Model Antitumor Assays | 10 | 2025 | 917 | 0.280 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2008 | 159 | 0.270 |
Why?
| | Receptors, Notch | 2 | 2022 | 87 | 0.270 |
Why?
| | Pyrimidines | 3 | 2020 | 510 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1791 | 0.240 |
Why?
| | Quartz | 1 | 2025 | 9 | 0.240 |
Why?
| | Antibodies | 3 | 2017 | 399 | 0.230 |
Why?
| | Gene Expression Regulation | 4 | 2013 | 2600 | 0.230 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | Immunotherapy, Adoptive | 2 | 2020 | 358 | 0.230 |
Why?
| | Cells, Cultured | 8 | 2020 | 4149 | 0.230 |
Why?
| | Mice, Inbred NOD | 8 | 2022 | 599 | 0.230 |
Why?
| | Polycomb Repressive Complex 1 | 3 | 2024 | 53 | 0.230 |
Why?
| | Purines | 4 | 2020 | 182 | 0.220 |
Why?
| | Antigens, Differentiation | 2 | 2017 | 78 | 0.220 |
Why?
| | Quinazolinones | 3 | 2020 | 19 | 0.220 |
Why?
| | Neoplasms, Experimental | 4 | 2019 | 174 | 0.220 |
Why?
| | Cancer Vaccines | 2 | 2020 | 165 | 0.220 |
Why?
| | Hedgehog Proteins | 3 | 2022 | 200 | 0.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2024 | 1439 | 0.210 |
Why?
| | Cellular Senescence | 2 | 2024 | 218 | 0.200 |
Why?
| | Phenylenediamines | 1 | 2023 | 12 | 0.200 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2017 | 428 | 0.190 |
Why?
| | Mice, SCID | 7 | 2020 | 367 | 0.190 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2020 | 76 | 0.190 |
Why?
| | Infratentorial Neoplasms | 1 | 2023 | 64 | 0.190 |
Why?
| | Benzamides | 1 | 2023 | 218 | 0.180 |
Why?
| | Electron Transport Complex I | 1 | 2022 | 42 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 65 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2024 | 528 | 0.180 |
Why?
| | Radiation Tolerance | 1 | 2022 | 104 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 211 | 0.170 |
Why?
| | Stomach Neoplasms | 1 | 2022 | 118 | 0.170 |
Why?
| | Brain Stem Neoplasms | 2 | 2012 | 83 | 0.170 |
Why?
| | Rituximab | 2 | 2019 | 204 | 0.170 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 211 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2021 | 311 | 0.160 |
Why?
| | Meningeal Neoplasms | 2 | 2018 | 97 | 0.160 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2019 | 28 | 0.160 |
Why?
| | Cell Tracking | 1 | 2019 | 17 | 0.150 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2019 | 70 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2020 | 154 | 0.150 |
Why?
| | NF-kappa B | 1 | 2023 | 684 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 555 | 0.140 |
Why?
| | Receptor, Notch1 | 1 | 2018 | 65 | 0.140 |
Why?
| | Osteosarcoma | 1 | 2019 | 73 | 0.140 |
Why?
| | Peptides | 4 | 2013 | 971 | 0.140 |
Why?
| | Myeloid Cells | 1 | 2019 | 147 | 0.140 |
Why?
| | Corpus Striatum | 2 | 2010 | 174 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2018 | 99 | 0.140 |
Why?
| | Appetite Regulation | 1 | 2017 | 32 | 0.130 |
Why?
| | Dorsal Raphe Nucleus | 1 | 2017 | 31 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1075 | 0.130 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 258 | 0.130 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 341 | 0.130 |
Why?
| | Neoplasms | 3 | 2021 | 2731 | 0.130 |
Why?
| | Azepines | 2 | 2014 | 99 | 0.130 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2017 | 65 | 0.120 |
Why?
| | Prazosin | 1 | 2016 | 25 | 0.120 |
Why?
| | Oncogene Protein v-akt | 1 | 2016 | 24 | 0.120 |
Why?
| | Antigens, Neoplasm | 1 | 2019 | 320 | 0.120 |
Why?
| | Contrast Media | 1 | 2019 | 476 | 0.120 |
Why?
| | Drug Repositioning | 1 | 2016 | 39 | 0.120 |
Why?
| | Protein Kinase C-delta | 1 | 2016 | 47 | 0.120 |
Why?
| | Transcription Factors | 2 | 2014 | 1706 | 0.120 |
Why?
| | Triazoles | 2 | 2014 | 163 | 0.120 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 435 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 918 | 0.120 |
Why?
| | Adenocarcinoma | 1 | 2022 | 897 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 565 | 0.120 |
Why?
| | Survival Analysis | 5 | 2017 | 1322 | 0.110 |
Why?
| | Calreticulin | 1 | 2015 | 22 | 0.110 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2015 | 41 | 0.110 |
Why?
| | Casein Kinase II | 1 | 2014 | 22 | 0.110 |
Why?
| | Huntingtin Protein | 3 | 2010 | 13 | 0.110 |
Why?
| | Structure-Activity Relationship | 2 | 2012 | 569 | 0.110 |
Why?
| | Toll-Like Receptors | 1 | 2015 | 187 | 0.100 |
Why?
| | Cell Death | 3 | 2011 | 386 | 0.100 |
Why?
| | Molecular Targeted Therapy | 2 | 2013 | 420 | 0.100 |
Why?
| | Antibody Specificity | 2 | 2011 | 183 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2020 | 1996 | 0.100 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 661 | 0.100 |
Why?
| | Disease Models, Animal | 6 | 2022 | 4414 | 0.100 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2013 | 60 | 0.100 |
Why?
| | Cell Differentiation | 3 | 2016 | 1983 | 0.100 |
Why?
| | Female | 16 | 2025 | 75814 | 0.100 |
Why?
| | Brain | 3 | 2020 | 2857 | 0.100 |
Why?
| | Apoptosis | 4 | 2025 | 2487 | 0.100 |
Why?
| | Nanoparticles | 1 | 2019 | 481 | 0.100 |
Why?
| | Mutation | 4 | 2025 | 4006 | 0.100 |
Why?
| | Xenopus laevis | 1 | 2012 | 104 | 0.090 |
Why?
| | Multiprotein Complexes | 1 | 2013 | 171 | 0.090 |
Why?
| | Mitochondria | 2 | 2022 | 962 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 163 | 0.090 |
Why?
| | Protein Kinases | 1 | 2013 | 307 | 0.090 |
Why?
| | Inflammation | 1 | 2023 | 2840 | 0.090 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2011 | 124 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 9 | 1 | 2010 | 18 | 0.080 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2010 | 19 | 0.080 |
Why?
| | Presynaptic Terminals | 1 | 2011 | 94 | 0.080 |
Why?
| | Cell Survival | 4 | 2018 | 1123 | 0.080 |
Why?
| | Single-Chain Antibodies | 1 | 2010 | 17 | 0.080 |
Why?
| | Prognosis | 5 | 2020 | 4080 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 908 | 0.080 |
Why?
| | Quality of Life | 1 | 2023 | 3024 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 428 | 0.080 |
Why?
| | Pineal Gland | 1 | 2010 | 15 | 0.080 |
Why?
| | Pinealoma | 1 | 2010 | 9 | 0.080 |
Why?
| | Immunotherapy, Active | 1 | 2010 | 9 | 0.080 |
Why?
| | Rats | 5 | 2011 | 5556 | 0.080 |
Why?
| | Immunohistochemistry | 4 | 2019 | 1724 | 0.080 |
Why?
| | Vaccines, Subunit | 1 | 2010 | 50 | 0.080 |
Why?
| | Male | 12 | 2024 | 70140 | 0.080 |
Why?
| | Neurodegenerative Diseases | 1 | 2011 | 141 | 0.080 |
Why?
| | Bevacizumab | 1 | 2010 | 135 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 352 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2022 | 630 | 0.070 |
Why?
| | Injections, Intraventricular | 2 | 2020 | 55 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2015 | 1144 | 0.070 |
Why?
| | Extracellular Matrix Proteins | 1 | 2010 | 156 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2010 | 334 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3734 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2020 | 7948 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2010 | 229 | 0.070 |
Why?
| | Antibodies, Blocking | 2 | 2018 | 36 | 0.070 |
Why?
| | Synapses | 1 | 2011 | 428 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1486 | 0.070 |
Why?
| | Adaptation, Physiological | 1 | 2011 | 561 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2012 | 2815 | 0.070 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1362 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 547 | 0.060 |
Why?
| | Down Syndrome | 1 | 2013 | 504 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2022 | 1992 | 0.060 |
Why?
| | Transcriptome | 2 | 2023 | 1007 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 2006 | 154 | 0.060 |
Why?
| | Archaeology | 1 | 2025 | 39 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5222 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 641 | 0.060 |
Why?
| | Heterografts | 2 | 2016 | 135 | 0.060 |
Why?
| | Gene Expression | 2 | 2010 | 1490 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1243 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 674 | 0.060 |
Why?
| | Receptors, AMPA | 1 | 2006 | 143 | 0.060 |
Why?
| | North America | 1 | 2025 | 304 | 0.050 |
Why?
| | Disease-Free Survival | 2 | 2017 | 713 | 0.050 |
Why?
| | Neoplasm Transplantation | 2 | 2015 | 251 | 0.050 |
Why?
| | BRCA2 Protein | 1 | 2024 | 62 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2015 | 6270 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 1979 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2025 | 167 | 0.050 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2024 | 83 | 0.050 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 303 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2012 | 1182 | 0.050 |
Why?
| | Gene Dosage | 2 | 2013 | 142 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1250 | 0.050 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2022 | 27 | 0.050 |
Why?
| | Blotting, Western | 3 | 2012 | 1220 | 0.050 |
Why?
| | Leucovorin | 1 | 2022 | 86 | 0.050 |
Why?
| | Esophagogastric Junction | 1 | 2022 | 52 | 0.050 |
Why?
| | Phenotype | 2 | 2024 | 3172 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 80 | 0.050 |
Why?
| | Cell Respiration | 1 | 2022 | 106 | 0.040 |
Why?
| | Electron Transport | 1 | 2022 | 116 | 0.040 |
Why?
| | Fluorouracil | 1 | 2022 | 207 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2010 | 1125 | 0.040 |
Why?
| | Electrons | 1 | 2022 | 88 | 0.040 |
Why?
| | NAD | 1 | 2022 | 78 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 213 | 0.040 |
Why?
| | Cell Separation | 2 | 2013 | 309 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6951 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 243 | 0.040 |
Why?
| | Drosophila | 1 | 2022 | 154 | 0.040 |
Why?
| | Aged | 5 | 2020 | 24836 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2013 | 959 | 0.040 |
Why?
| | Child | 4 | 2024 | 22390 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 310 | 0.040 |
Why?
| | Middle Aged | 5 | 2022 | 34658 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 261 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2020 | 204 | 0.040 |
Why?
| | Indazoles | 1 | 2020 | 77 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2020 | 325 | 0.040 |
Why?
| | Morpholines | 1 | 2020 | 129 | 0.040 |
Why?
| | Pyrazines | 1 | 2020 | 88 | 0.040 |
Why?
| | Epitopes | 2 | 2011 | 476 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 983 | 0.040 |
Why?
| | Twist-Related Protein 1 | 1 | 2018 | 9 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2019 | 11216 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2022 | 338 | 0.040 |
Why?
| | Medical Oncology | 1 | 2021 | 316 | 0.040 |
Why?
| | Parabiosis | 1 | 2018 | 11 | 0.040 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2018 | 19 | 0.040 |
Why?
| | Europe | 1 | 2019 | 408 | 0.030 |
Why?
| | Ovarian Neoplasms | 1 | 2024 | 581 | 0.030 |
Why?
| | Surface Properties | 1 | 2019 | 412 | 0.030 |
Why?
| | Sulfonamides | 1 | 2022 | 576 | 0.030 |
Why?
| | Particle Size | 1 | 2019 | 403 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 115 | 0.030 |
Why?
| | Mice, Obese | 1 | 2017 | 65 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 700 | 0.030 |
Why?
| | Rats, Nude | 1 | 2017 | 23 | 0.030 |
Why?
| | Allografts | 1 | 2018 | 148 | 0.030 |
Why?
| | Hunger | 1 | 2017 | 54 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2554 | 0.030 |
Why?
| | Immunocompetence | 1 | 2017 | 44 | 0.030 |
Why?
| | Electrophysiology | 1 | 2017 | 218 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 771 | 0.030 |
Why?
| | Animals, Newborn | 2 | 2011 | 866 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 5866 | 0.030 |
Why?
| | Optogenetics | 1 | 2017 | 109 | 0.030 |
Why?
| | Monocytes | 1 | 2019 | 544 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1108 | 0.030 |
Why?
| | Fasting | 1 | 2017 | 283 | 0.030 |
Why?
| | Up-Regulation | 1 | 2018 | 851 | 0.030 |
Why?
| | Fetus | 1 | 2020 | 797 | 0.030 |
Why?
| | Phenazines | 1 | 2014 | 12 | 0.030 |
Why?
| | Naphthyridines | 1 | 2014 | 19 | 0.030 |
Why?
| | Zinc Finger Protein Gli2 | 1 | 2014 | 4 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 26 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 716 | 0.030 |
Why?
| | Models, Biological | 2 | 2017 | 1810 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2013 | 20 | 0.030 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 10 | 0.030 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2014 | 67 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 507 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2013 | 62 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 156 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2019 | 2165 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 75 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2013 | 42 | 0.030 |
Why?
| | Gene Amplification | 1 | 2013 | 105 | 0.030 |
Why?
| | Adult Stem Cells | 1 | 2013 | 40 | 0.020 |
Why?
| | Ubiquitination | 1 | 2013 | 107 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2014 | 191 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 910 | 0.020 |
Why?
| | Spheroids, Cellular | 1 | 2013 | 78 | 0.020 |
Why?
| | Body Weight | 1 | 2017 | 992 | 0.020 |
Why?
| | Antibodies, Bispecific | 1 | 2013 | 59 | 0.020 |
Why?
| | Mammary Glands, Animal | 1 | 2013 | 127 | 0.020 |
Why?
| | Trisomy | 1 | 2013 | 78 | 0.020 |
Why?
| | Epithelium | 1 | 2013 | 311 | 0.020 |
Why?
| | beta Catenin | 1 | 2014 | 256 | 0.020 |
Why?
| | Immunoconjugates | 1 | 2013 | 127 | 0.020 |
Why?
| | Ligands | 1 | 2014 | 665 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 5 | 1 | 2011 | 4 | 0.020 |
Why?
| | Colforsin | 1 | 2011 | 48 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2016 | 508 | 0.020 |
Why?
| | RNA Interference | 1 | 2013 | 465 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2011 | 41 | 0.020 |
Why?
| | Biophysical Phenomena | 1 | 2011 | 68 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 206 | 0.020 |
Why?
| | Glycoproteins | 1 | 2013 | 354 | 0.020 |
Why?
| | Drosophila melanogaster | 1 | 2013 | 234 | 0.020 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2011 | 44 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2011 | 81 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4599 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 2011 | 157 | 0.020 |
Why?
| | Child, Preschool | 2 | 2020 | 11511 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 3042 | 0.020 |
Why?
| | Nerve Fibers | 1 | 2011 | 100 | 0.020 |
Why?
| | Molecular Weight | 1 | 2011 | 326 | 0.020 |
Why?
| | Cell Aggregation | 1 | 2011 | 23 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2808 | 0.020 |
Why?
| | Nestin | 1 | 2011 | 20 | 0.020 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2011 | 22 | 0.020 |
Why?
| | Anesthetics, Local | 1 | 2011 | 101 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2011 | 58 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2015 | 2146 | 0.020 |
Why?
| | Pons | 1 | 2011 | 29 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2011 | 279 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2011 | 291 | 0.020 |
Why?
| | Antigens, CD | 1 | 2013 | 537 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2010 | 60 | 0.020 |
Why?
| | Cross Reactions | 1 | 2010 | 132 | 0.020 |
Why?
| | Nerve Degeneration | 1 | 2010 | 49 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2911 | 0.020 |
Why?
| | Cell Division | 1 | 2012 | 792 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 408 | 0.020 |
Why?
| | Isoenzymes | 1 | 2010 | 296 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2010 | 377 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 628 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1244 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 191 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2011 | 738 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2079 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2010 | 211 | 0.020 |
Why?
| | Nerve Net | 1 | 2011 | 276 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2010 | 397 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2010 | 627 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2012 | 696 | 0.020 |
Why?
| | Fibroblasts | 1 | 2013 | 1018 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1013 | 0.020 |
Why?
| | Bicuculline | 1 | 2006 | 22 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2006 | 35 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2006 | 199 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2511 | 0.020 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2006 | 106 | 0.020 |
Why?
| | Hippocampus | 1 | 2011 | 937 | 0.020 |
Why?
| | Infant | 1 | 2020 | 9820 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2006 | 319 | 0.010 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2006 | 142 | 0.010 |
Why?
| | Drug Interactions | 1 | 2006 | 404 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 1035 | 0.010 |
Why?
| | Neostriatum | 1 | 2004 | 36 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1059 | 0.010 |
Why?
| | Transfection | 1 | 2006 | 932 | 0.010 |
Why?
| | Adult | 2 | 2020 | 39319 | 0.010 |
Why?
| | Adolescent | 2 | 2015 | 22116 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2006 | 457 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 835 | 0.010 |
Why?
| | United States | 1 | 2019 | 15298 | 0.010 |
Why?
| | Vaccination | 1 | 2010 | 1468 | 0.010 |
Why?
| | Calcium | 1 | 2006 | 1175 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 2863 | 0.010 |
Why?
| | Lung | 1 | 2010 | 4051 | 0.010 |
Why?
|
|
Mitra's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|